Brussels (Belgium), 26th June 2023 – UCB, a global biopharmaceutical company, today announced that the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis remains under…Original Article
UCB Provides Update on U.S. FDA Review of the Biologics License Application for Bimekizumab
